1、novotech-MAY 8,2024Non-Small Cell Lung Cancer-Global Clinical Trial Landscape(2024)The Asia-Pacific region shows shorter recruitment durations and faster recruitment rates compared to the USNSCLC originates from larger cells lining the airways or mucus-producing cellsNSCLC constitutes about 85%of al

2、l lung cancersMarketed drugs include small molecules targeting KRAS and EGFR,such as Lumakras and Tagrisso as well as monoclonal antibodies like MvasiPhase III pipeline drugs,such as bispecific or multispecific antibodies like KN046 and ivonescimab,indicate a shift towards more targeted and personal

3、ized treatment approachesThe content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the prior writte

4、n permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech.Any unauthorized

5、reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-#DYK Did youknow?In the Asia-Pacific region,China reported the highest NSCLC casesThe United S

6、tates reported the highest number of NSCLC cases in North AmericaIn Europe,Germany reported a relatively higher incidence of NSCLCIn ROW,Brazil reported the highest incidence of NSCLCTRIAL CONTRIBUTIONSNON-SMALL CELL LUNG CANCER(NSCLC)GLOBAL CLINICAL TRIAL LANDSCAPE(2024)40%ASIA-PACIFICled by Mainla